MKUltra Lives: NIMH Funds Unethical Brain Experiments On Live Human Subjects

Statement Offered for the Congressional Record

Chairwoman Anna Paulina Luna has announced the House Oversight Task Force on the Declassification of Federal Secrets will hold a hearing June 30 on MKUltra.

As the Task Force examines MKUltra’s legacy of government-sanctioned mind and behavior alteration conducted without meaningful consent, I hope they will extend that scrutiny to current federally funded medical research that deliberately induces dissociative states. These studies — primarily involving psilocybin and ketamine — proceed with the approval and financial support of the National Institutes of Health and its National Institute of Mental Health. The lessons of MKUltra are not confined to the archives; they echo in today’s taxpayer-funded laboratories.

The research at issue divides into two categories that must be analyzed separately, because they fail on different ethical grounds. Challenge paradigms deliberately induce psychosis-like symptoms, dissociation, and ego dissolution in subjects — frequently healthy volunteers — for the purpose of mechanistic insight. Therapeutic protocols administer compounds to patients with diagnosed conditions for purposes of treatment. In the context of induced dissociative states, the first category is unethical at the design stage, before any consent question arises. The second category may be defensible in principle but fails at the consent stage, because the intervention disables the very faculty that consent requires. I address each in turn.

I. Challenge Paradigms Violate Federal Research Ethics at the Design Stage

For decades, NIMH-supported researchers have administered subanesthetic doses of ketamine to healthy volunteers and schizophrenia patients specifically to induce transient dissociative and psychosis-like states. The stated goal is to “model” schizophrenia symptoms in real time: positive symptoms (hallucinations, delusions), negative symptoms, cognitive disruption, and profound dissociation. Prominent NIMH-funded investigators, including those at the Maryland Psychiatric Research Center and the University of Alabama at Birmingham, have published extensively on these protocols. Recent NIMH intramural studies continue to explore repeated ketamine dosing and neuroimaging under federal grants, and active 2026 NIMH grants such as R01MH142698 ($871k) and R01MH133849 ($517k) further support research that relies on the same induced altered states. Because ketamine is generic, these experiments rely almost entirely on taxpayer dollars through NIMH extramural and intramural funding streams.

These are not fringe experiments. NIMH’s intramural Protocol 17-M-0060 continues to administer repeated ketamine infusions to induce dissociative states while measuring brain changes. A newly launched $21 million NIH initiative — including Emory University as a major site — is now testing psilocybin in healthy older adults precisely to induce profound depersonalization, derealization, and ego dissolution. NIMH and NIDA strategic plans continue to prioritize these paradigms under the banners of “mechanism discovery” and “treatment innovation.”

Research participants in ketamine studies have reported profoundly distressing subjective experiences beyond the drug infusion window. In a 2017 case report, two patients with treatment-resistant depression described severe psychotomimetic effects following rapid S-(+)-ketamine infusions. One patient perceived a devil removing his heart and characterized the episode as a “terrible experience,” followed by persistent dissociative thoughts and nightmares for approximately one week. The second patient experienced bodily disintegration into atoms, sensations of death, and bodily explosion (“It was death. I died… am I here? My body exploded”), which he found traumatic, with symptoms persisting for nearly four weeks. These accounts underscore the potential for ketamine to induce subjectively traumatic states that extend beyond the infusion period, even in supervised clinical settings.

Rep. Anna Paulina Luna on social media platform X, April 30, 2026

Challenge paradigms fail the Belmont Report’s principle of beneficence at the threshold. The risk-benefit calculus that governs all federally funded human subjects research cannot balance in a challenge study, because the subject — particularly the healthy volunteer — receives no therapeutic benefit. The benefit accrues to the researcher, to the field, and maybe at some attenuated future point to the hypothetical patient. What the subject receives is harm: transient at minimum, potentially durable, and in the case of healthy-volunteer protocols, harm that is the entire point of the protocol rather than a side effect to be minimized. The Nuremberg Code’s second and third principles compound this defect, requiring that experiments yield results unprocurable by other means and be designed to avoid unnecessary suffering. The Declaration of Helsinki preserves a sharper distinction between therapeutic and non-therapeutic research than American practice now observes, imposing a stricter risk standard on the latter precisely because the subject is not a patient seeking treatment.

In ketamine challenge studies conducted on healthy volunteers, consent documents describe the induction of dissociation and psychosis-like symptoms without adequately conveying how such states may render meaningful withdrawal of consent practically impossible once the infusion begins. Experts have documented that consent documents often fail to convey these risks in concrete, experiential terms that prospective participants can meaningfully appreciate, particularly when the subjective effects are difficult to describe to someone who has never encountered them.

But even the best informed consent cannot cure the structural design defect. Even a hypothetically perfect consent — a subject with full comprehension, no power asymmetry, complete capacity throughout — cannot rehabilitate a protocol whose design requires harming a healthy person to generate data. Consent can authorize a subject to accept risk in pursuit of benefit. It cannot authorize a researcher to inflict harm in the absence of benefit to the subject, because the ethical defect is in the structure of the transaction, not in the subject’s awareness of it. Such challenge paradigms are categorically unethical, and no procedural reform — better consent forms, more elaborate review, additional disclosures — can reach the underlying violation.

II. Therapeutic Protocols Fail at the Consent Stage

Therapeutic psilocybin research, often framed as “psychedelic-assisted therapy,” presents a distinct ethical problem. Since the subject is a patient with a diagnosed condition — treatment-resistant depression, PTSD, end-of-life distress — the intervention is aimed at her benefit, therefore the design-stage objection that defeats such research on healthy subjects does not apply. Yet the consent problem in therapeutic dissociation research is not merely procedural; it is structural, and it cannot be cured by better forms.

A. Protocols that produce anosognosia make withdrawal of consent impossible

Informed consent presupposes a subject capable of evaluating the nature of the intervention, weighing its risks against its benefits, and retaining the capacity to withdraw consent. Dissociative protocols deliberately abolish precisely those faculties. A participant cannot meaningfully consent to ego dissolution before experiencing it, because the experience by definition disrupts the metacognitive apparatus that consent requires; once inside the dissociative state, the participant lacks reliable access to the self that signed the form. The induced state produces anosognosia: it impairs the participant’s capacity to recognize that her capacity is impaired. Researchers and Institutional Review Boards (IRBs) have responded by creating more elaborate consent documents — disclosures of “challenging experiences,” “ego dissolution,” “psychological vulnerability” — but elaboration of language does not solve a problem that is categorical rather than informational. No quantity of disclosure language can transmit the phenomenological content of depersonalization to a subject who has not yet been depersonalized, and no signature obtained beforehand can be ratified from within the altered state. The consent obtained is consent in form but not in substance — a procedural artifact that satisfies regulatory checkboxes while failing the moral function the doctrine of informed consent is meant to perform.

This is not an abstract philosophical objection; it identifies a violation of the federal research ethics framework already binding on every NIH-and NIMH-funded protocol. The federal Common Rule (45 CFR 46) requires that informed consent be both legally effective and obtained under circumstances that provide the prospective subject “sufficient opportunity to consider whether or not to participate” — a standard that presumes continuous capacity to evaluate participation, not capacity at a single pre-dose moment. The Common Rule further requires IRBs to provide additional safeguards when subjects are “likely to be vulnerable to coercion or undue influence” — vitally important for test subjects already under treatment for mental health concerns or end of life distress. The Belmont Report’s principle of respect for persons demands recognition of subjects as autonomous agents throughout the research encounter. The Declaration of Helsinki provides in Article 26 that subjects must be informed of the right to withdraw consent “at any time without reprisal” — a right rendered meaningless when the intervention itself disables the faculty of withdrawal. Congress need not legislate new ethical standards to act on therapeutic protocols. It needs only to enforce the ones already on the books.

The clinical record reflects these structural defects. Qualitative research on psilocybin-assisted therapy for PTSD in veterans has documented intense emotional flooding, dissociation, and trauma reactivation during sessions, with participants varying in their ability to integrate the experiences. In one published case study, a participant in a trial for treatment-resistant depression experienced a harrowing high-dose session that triggered increased suicidal ideation, severe eating difficulties, and a stark confrontation with suppressed trauma described as “ripping the lid off” suppressed emotions; although later reframed by the individual as beneficial, the acute distress was profound. Another first-person account from a high-dose trial participant described an initial helpful session followed by a second that was deeply challenging — described as a “reverse religious experience” involving terror, panic, and lasting negative impacts on identity and emotional processing. Recent research has formally proposed psychedelic iatrogenic structural dissociation as a recognized risk category. These accounts are not aberrations to be designed around. They are the predictable consequences of an intervention whose mechanism is the disruption of the self.

B. Deficiencies in Information and Consent Protocols

Even setting aside the categorical concerns with the induction of dissociative states in therapeutic trials, the informed consent and preparatory protocols themselves independently render this research unethical. Under the Common Rule and the Declaration of Helsinki, valid informed consent requires that prospective participants receive a complete, comprehensible, and balanced description of the study’s risks, benefits, and procedures in language they can understand — without undue influence or the creation of unrealistic expectations. Yet publicly available consent forms and preparatory manuals for psilocybin trials routinely employ quasi-religious, non-empirical terminology that frames the drug-induced state in highly positive, transformative terms. Participants are explicitly prepared for “mystical” or “transformative experiences” that may include “substantial and sustained personal meaning and spiritual significance.” Protocols and manuals (including the influential Yale Manual for Psilocybin-Assisted Therapy) direct therapists to provide psychoeducation that clarifies participants’ expectations around these profound, life-enhancing outcomes while building rapport and encouraging surrender to the experience. Outcome measures such as the Mystical Experience Questionnaire (MEQ30) embed this subjective “mystical” benchmark as a central scientific endpoint.

This language is not neutral or strictly empirical; it sets unreasonable expectations of profound personal transformation while under-emphasizing the concrete risks of acute dissociation, psychological distress, long-term perceptual changes, personality shifts, or altered metaphysical beliefs. Recent analyses describe these effects as epistemically transformative — that is, effects that cannot be evaluated in advance by a participant who has not yet experienced them.

These practices fail the Common Rule’s requirements for comprehension and voluntariness, and they fail the Declaration of Helsinki’s emphasis on respect for persons. The preparatory protocols are not incidental to the trial design; they are integral to it. When preparatory sessions frame ego dissolution as a therapeutic mystical or transcendent experience, and consent forms rely on subjective, non-scientific benchmarks, the result is a systemic ethical failure. The form is being completed; the moral function the doctrine of informed consent is meant to perform is not.

III. Operational Migration: When Research Ethics Erode, Practice Follows

The ethical erosion in research settings has migrated into operational practice, with predictable results. The Hennepin Healthcare ketamine studies at Hennepin County Medical Center in Minneapolis involved paramedics administering ketamine to agitated patients in pre-hospital and emergency settings, often at police urging, under an “exception from informed consent” for emergency treatment. Patients — frequently from vulnerable, marginalized populations — received the drug without their knowledge or consent. Investigations and bioethics analyses revealed serious respiratory complications (including intubation in a significant percentage of cases), inadequate oversight, and troubling ties between researchers, law enforcement, and sedation practices. A June 2025 Undark investigation detailed the “patchwork policies” governing ketamine therapy clinics across states, highlighting inconsistent medical oversight, variable provider training, and the ease with which patients experience dissociative effects with minimal safeguards.

Hennepin is the operational consequence of normalizing induced dissociation as a legitimate medical tool: once the research community treats the deliberate fracture of consciousness as a routine intervention, the practice migrates into emergency settings where consent waivers, racial disparities, and law enforcement entanglement compound the underlying ethical defect. Proponents insist safeguards, ethics board approval, and consent forms protect participants. Yet MKUltra’s documented abuses occurred under the same banner of scientific necessity. The difference today is procedural: today’s experiments carry IRB stamps and publish in peer-reviewed journals, yet the core violation remains — the deliberate fracture of human consciousness, conducted on subjects who in the case of challenge paradigms derive no benefit from the harm inflicted, and in the case of therapeutic protocols cannot meaningfully consent to the intervention from within it.

Proponents insist safeguards, ethics board approval, and consent forms protect participants. Yet MKUltra’s documented abuses occurred under the same banner of scientific necessity. The difference today is procedural: today’s experiments carry IRB stamps and publish in peer-reviewed journals, yet the core violation remains — the deliberate fracture of human consciousness, conducted on subjects who in the case of challenge paradigms derive no benefit from the harm inflicted, and in the case of therapeutic protocols cannot meaningfully consent to the intervention from within it.

IV. The Funding Logic Underwriting Challenge Research

The ethical defect at the design stage of challenge paradigms is compounded by an epistemic defect upstream of it. NIMH funds invasive animal experiments — including the deliberate induction of psychiatric symptoms in monkeys, rodents, and other species — on the rationale that such work will translate into clinical benefit. The empirical record establishes that translation rarely occurs. A 2023 review found that the failure rate for translation of drugs from animal testing to human treatments has remained above 92% for several decades, with most failures attributable to unexpected toxicity revealed only in human trials or to outright lack of efficacy. A 2024 analysis examining 376 therapies across 54 human diseases found that only 5% of animal-tested therapeutic interventions ultimately obtain regulatory approval for human application, with median transition times of ten years from animal study to approval.

The institute nevertheless continues to fund such research, and when the animal models predictably fail to capture the phenomenology of human psychiatric conditions, that very failure is offered as the justification for human challenge studies. The taxpayer pays twice for the same epistemic failure: first for the animal research that does not translate, then for the human research justified by the inadequacy of the animal research. The human subjects of the second round bear the resulting risk.

The pattern is illustrated by NIMH expenditures recently catalogued in congressional oversight materials, including over $14 million to teach monkeys to play a Price Is Right-inspired video game and over $1 million to study binge drinking in adolescent ferrets. These are not isolated curiosities; they exemplify a funding architecture in which speculative animal models are sustained despite their documented failure to produce translational benefit, while the same institute concurrently funds human challenge protocols on the rationale that better mechanistic data is needed.

This funding logic also frames the broader return on the institute’s investment. Since the National Institutes of Health declared the 1990s the “Decade of the Brain,” NIMH has invested tens of billions of taxpayer dollars in neuroscience, genomics, and brain research, with the promise of transformative treatments for severe mental illness. Over the subsequent decades there has been no commensurate reduction in the incidence, prevalence, or long-term burden of conditions such as schizophrenia, bipolar disorder, or treatment-resistant depression. Suicide rates, chronic disability, and psychiatric hospitalization trends have not shown sustained improvement despite this massive investment. A January 2025 Manhattan Institute analysis of NIH practices documents how misaligned priorities and inefficient allocation have contributed to disappointing returns on mental health research spending, with limited translation into better clinical outcomes for the most disabled patients. The Task Force should consider that the human challenge research at issue in this testimony is not an aberration within an otherwise well-functioning research enterprise. It is the predictable downstream consequence of an upstream funding architecture that has been failing for decades yet continues to receive federal support despite that record.

These institutional patterns acquire new urgency in the current policy moment. The President’s April 18, 2026 Executive Order provides a comprehensive acceleration framework for psychedelic drugs that have received FDA Breakthrough Therapy designation, expanding clinical trial participation, data sharing across HHS, FDA, and VA, and patient access pathways including Right to Try. The structural ethics violations identified in this statement make congressional oversight of the underlying research ethics framework even more urgent; acceleration without commensurate oversight of the consent architecture and trial design integrity exposes a larger population to the structural defects this statement identifies.

V. Recommended Actions

The federal disclosure regime overseeing the research at issue here has failed in documented and quantifiable ways across federally funded research generally. A 2023 JAMA analysis of NIH-funded pediatric clinical trials completed between 2017 and 2019 found that 137 trials enrolling 41,501 children — funded with $362 million in taxpayer dollars — never made their results public in any form. Just 13 percent of finished trials were registered within twelve months of completion as required, and the researchers estimated only a 54 percent likelihood that results would be published even four years after grant completion. If the same regulatory architecture cannot produce timely disclosure of ordinary pediatric research, then the American public has no basis for confidence in meaningful oversight of protocols whose mechanism is the deliberate disruption of consciousness. The following recommendations proceed from that recognition.

I respectfully request that the Task Force:

• Include modern medically-induced dissociation research, including “challenge” studies as well as protocols labeled “therapeutic,” in its oversight inquiry, and recognize that the two categories require distinct ethical analyses and distinct remedies.

• Demand full transparency on all current and recent NIH/NIMH grants supporting psilocybin and ketamine challenge or sedation studies.

• Recommend immediate suspension of federal funding for any challenge protocol whose primary or secondary aim is the deliberate induction of dissociative states in subjects who derive no therapeutic benefit, on the ground that such protocols violate the Belmont Report’s principle of beneficence and the Nuremberg Code’s second and third principles at the design stage.

• Direct the Government Accountability Office to audit informed consent practices in federally funded therapeutic dissociation research, with specific attention to whether the continuous-consent requirements of 45 CFR 46 and Article 26 of the Declaration of Helsinki can be satisfied by protocols whose mechanism is the disruption of the consenting subject’s metacognitive capacity.

• Hold additional hearings focused on the ethical limits of consent in consciousness-altering research and real-world applications such as pre-hospital sedation. Invite testimony from research participants who experienced acute and persistent dissociative effects.

Oversight is performative unless it produces meaningful change. The lessons of MKUltra are not confined to dusty archives. They are being repeated today, in plain view, funded with our tax dollars. Congress must act to protect the integrity of the human mind from unethical state-sponsored experimentation.

Amy Suzanne Martin, MA JD

Digital pdf version: MKUltra_Statement_Final